Stay updated on Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page.
Latest updates to the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page
- Check4 days agoChange DetectedNew results have been posted detailing various efficacy endpoints such as Progression-Free Survival (PFS), Overall Survival (OS), and Objective Response Rate (ORR) based on RECIST v1.1 assessments, alongside patient-reported outcomes and adverse event data, marking significant updates in the study's findings.SummaryDifference56%
- Check12 days agoChange DetectedThe website has been updated to Revision v2.11.0, while the previous version v2.10.5 has been removed, along with a notice regarding delays in displaying study record information.SummaryDifference0.5%
- Check19 days agoChange DetectedClinicalTrials.gov is addressing delays in displaying study record information, and the site has been updated to version 2.10.5, replacing the previous version 2.10.3.SummaryDifference0.5%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe website has been updated from version 2.10.2 to 2.10.3, indicating a new release.SummaryDifference0.0%
- Check55 days agoChange DetectedThe website has been updated from version 2.10.0 to 2.10.2, indicating new features or improvements in the latest release.SummaryDifference0.0%
- Check62 days agoChange DetectedResults have been submitted, replacing the previous status of no results posted.SummaryDifference0.1%
Stay in the know with updates to Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page.